Disorders of hemostasis in dialysis patients

Principles and Practice of Dialysis

Volumn , Issue , 2012, Pages 489-498

  Remuzzi, Giuseppe ^a,b   Galbusera, Miriam ^a   Boccardo, Paola ^a  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^b OSPEDALI RIUNITI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84938752302     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (97)

1. Morgagni GB. Opera Omnia. Ex Typographia Remondiniana. Venezia, 1764.
2. Mattix H, Singh AK. Is the bleeding time predictive of bleeding prior to a percutaneous renal biopsy. Curr Opin Nephrol Hypertens 1999;8:715-718.
3. Eknoyan G, Wacksman SJ, Glueck HI, et al. Platelet function in renal failure. N Engl J Med 1969;280:677-681.
4. Di Minno G, Martinez J, McKean M, et al. Platelet dysfunction in uremia: multifaceted defect partially corrected by dialysis. Am J Med 1985;79:552-559.
5. Eknoyan G, Brown CH. Biochemical abnormalities of platelets in renal failure: evidence for decreased platelet serotonin, adenosine diphosphate and Mg-dependent adenosine triphosphatase. Am J Nephrol 1981;1:17-23.
6. Kyrie PA, Stockenhuber F, Brenner BM, et al. Evidence for an increased generation of prostacyclin in the microvasculature and an impairment of the platelet alpha-granule release in chronic renal failure. Thromb Haemost 1988;60:205-208.
7. Vlachoyannis J, Schoeppe W. Adenylate cyclase activity and cAMP content of human platelets in uremia. Eur J Clin Invest 1982;12:379-381.
8. Jacobsson B, Ransnas L, Nyberg G, et al. Abnormality of adenylate cyclase regulation in human platelet membranes in renal insufficiency. Eur J Clin Invest 1985;15:75-81.
9. Gura V, Creter D, Levi J. Elevated thrombocyte calcium content in uremia and its correction by 1-(OH) vitamin D treatment. Nephron 1982;30:237-239.
10. Ware JA, Clark BA, Smith M, et al. Abnormalities of cytoplasmic Ca2+ in platelets from patients with uremia. Blood 1989;73:172-176.
11. Remuzzi G, Benigni A, Dodesini P, et al. Parathyroid hormone inhibits human platelet function. Lancet 1981;2:1321-1323.
12. Benigni A, Livio M, Dodesini P, et al. Inhibition of human platelet aggregation by parathyroid hormone: is cyclic AMP implicated? Am J Nephrol 1985;5:243-247.
13. Vigan G, Gotti E, Comberti E, et al. Hyperparathyroidism does not influence the abnormal primary haemostasis in patients with chronic renal failure. Nephrol Dial Transplant 1989;4:971-974.
14. Joist JH, Remuzzi G, Mannucci PM. Abnormal bleeding and thrombosis in renal disease. In: Colman RW, et al. eds. Hemostasis and thrombosis: basic principles and clinical practice. Philadelphia: JB Lippincott Co, 1994:921-935.
15. Smith MC, Dunn MJ. Impaired platelet thromboxane production in renal failure. Nephron 1981;29:133-137.
16. Remuzzi G, Benigni A, Dodesini P, et al. Reduced platelet thromboxane formation in uremia: evidence for a functional cyclooxygenase defect. J Clin Invest 1983;71:762-768.
17. Macconi D, Vigan G, Bisogno G, et al. Defective platelet aggregation in response to platelet-activating factor in uremia associated with low platelet thromboxane A2 generation. Am J Kidney Dis 1992;19:318-325.
18. Escolar G, Diaz-Ricart M, Cases A, et al. Abnormal cytoskeletal assembly in platelets from uremic patients. Am J Pathol 1993;143: 823-831.
19. Remuzzi G, Perico N, Zoja C, et al. Role of endothelium-derived nitric oxide in the bleeding tendency of uremia. J Clin Invest 1990;86:1768-1771.
20. Radomski MW, Palmer RMJ, Moncada S. The role of nitric oxide and cGMP in platelet adhesion to vascular endothelium. Biochem Biophys Res Commun 1987;148:1482-1489.
21. Aiello S, Noris M, Todeschini M, et al. Renal and systemic nitric oxide synthesis in rats with renal mass reduction. Kidney Int 1997;52:171-181.
22. Noris M, Benigni A, Boccardo P, et al. Enhanced nitric oxide synthesis in uremia: implications for platelet dysfunction and dialysis hypotension. Kidney Int 1993;44:445-450.
23. Noris M, Remuzzi G. Uremic bleeding: closing the circle after 30 years of controversies? Blood 1999;94:2569-2574.
24. Horl WH. Hemodialysis membrane: interleukins, biocompatibility and middle molecules. J Am Soc Nephrol 2002;13:S62-S71.
25. Mezzano B, Tagle R, Panes O, et al. Hemostatic disorder of uremia: the platelet defect, main determinant of the prolonged bleeding time, is correlated with indices of activation of coagulation and fibrinolysis. Thromb Haemost 1996;76:312-321.
26. Sloand EM, Sloand JA, Prodouz K, et al. Reduction of platelet glycoprotein Ib in uraemia. BrJHaematol 1991;77:375-381.
27. Benigni A, Boccardo P, Galbusera M, et al. Reversible activation defect of the platelet glycoprotein IIb-IIIa complex in patients with uremia. Am J Kidney Dis 1993;22:668-676.
28. Escolar G, Cases A, Bastida E, et al. Uremic platelets have a functional defect affecting the interaction of von Willebrand factor with glycoprotein IIb-IIIa. Blood 1990;76:1336-1340.
29. Rabiner SF, Molinas F. The role of phenol and phenolic acid on the thrombocytopathy and defective platelet aggregation of patients with renal failure. Am J Med 1970;49:346-351.
30. Horowitz HI, Stein IM, Cohen BD, et al. Further studies on the platelet inhibiting effect of guanidinosuccinic acid and its role in uremic bleeding. Am J Med 1970;49:336-340.
31. Remuzzi G, Livio M, Marchiaro G, et al. Bleeding in renal failure: altered platelet function in chronic uraemia only partially corrected by haemodialysis. Nephron 1978;22:347-353.
32. Stein IM, Cohen BD, Horowitz HI. Guanidino succinic acid: the 'X' factor in uremic bleeding? (Abstract) Clin Res 1968;16:397.
33. Rabiner SF. Bleeding in uremia. Med Clin North Am 1972;56:221-223.
34. Remuzzi G, Cavenaghi AE, Mecca G, et al. Prostacyclin-like activity and bleeding in renal failure. Lancet 1977;2:1195-1197.
35. Leithner CH, Winter M, Sibauer K, et al. Enhanced prostacyclin availability of blood vessels in uraemic humans and rats. In: Robinson RHB, et al., eds. Dialysis transplantation nephrology, Proceedings of the 15th Congress of European Dialysis and Transplant Association. Tunbridge Wells: Pitman Medical, 1978:418-22.
36. Defreyn G, Vergara Dauden M, Machin SJ, et al. A plasma factor in uraemia which stimulates prostacyclin release from cultured endothelial cells. Thromb Res 1980;19:695-699.
37. Saglikes Y, Massry SG, Iseki K, et al. Effect of PTH on blood pressure and response to vasoconstrictor agonists. Am J Physiol 1985;248:F674-F681.
38. Turitto WT, Weiss HJ. Red blood cells: their dual role in thrombus formation. Science 1980;207:541-543.
39. Livio M, Gotti E, Marchesi D, et al. Uraemic bleeding: role of anemia and beneficial effect of red cell transfusions. Lancet 1982;2:1013-1015.
40. Fernandez F, Goudable C, Sie P, et al. Low hematocrit and prolonged bleeding time in uraemic patients: effect of red cell transfusions. Br J Haematol 1985;59:139-148.
41. Aznar-Salatti J, Hernandez R, Anton P, et al. Serum obtained from uraemic patients modifies the reactivity towards platelets of extracellular matrices produced by endothelial cells (Abstract). VIth Int Sym Biol Vasc Cells 1990;1:57.
42. Gordge MP, Leaker BR, Patel A, et al. Recombinant human erythropoietin corrects uraemic bleeding without causing intravascular haemostatic activation. Thromb Res 1990;57:171-182.
43. Moia M, Mannucci PM, Vizzotto L, et al. Improvement in the haemostatic defect of uraemia after treatment with recombinant human erythropoietin. Lancet 1987;2:1227-1229.
44. Vigan G, Benigni A, Mendogni D, et al. Recombinant human erythropoietin to correct uremic bleeding. Am J Kidney Dis 1991;1:44-49.
45. Macdougall IC. Role of uremic toxins in exacerbating anemia in renal failure. Kidney Int 2001;59:S67-S72.
46. Andrassy K, Ritz E. Uremia as a cause of bleeding. Am J Nephrol 1985;5:313-319.
47. Shattil S, Bennett J, McDonough M, et al. Carbenicillin and penicillin G inhibit platelet function in vitro by impairing the interaction of agonists with the platelets surface. J Clinc Invest 1980;65:329-337.
48. Harter HR, Burch JW, Majerus PW, et al. Prevention of thrombosis in patients on hemodialysis by low dose of aspirin. N Engl J Med 1979;301:577-579.
49. Lindsay RM, Ferguson D, Prentice CR, et al. Reduction of thrombus formation on dialyzer membranes by aspirin and RA233. Lancet 1972;2:1287-1290.
50. Gaspari F, Vigan G, Orisio S, et al. Aspirin prolongs bleeding time in uremia by a mechanism distinct from platelet cyclo-oxygenase inhibition. J Clin Invest 1987;79:1788-1797.
51. Boyle JM, Johnston B. Acute upper gastrointestinal hemorrhage in patients with chronic renal disease. Am J Med 1983;75:409-412.
52. Harker LA, Fuster V. Pharmacology of platelet inhibitors. J Am Coll Cardiol 1986;8:21B-32B.
53. Margolis DM, Saylor JL, Geisse G, et al. Upper gastrointestinal disease in chronic renal failure: a prospective evaluation. Arch Intern Med 1978;138:1214-1217.
54. Dave PB, Romeu J, Antonelli A, et al. Gastrointestinal telangiectasias: a source of bleeding in patients receiving hemodialysis. Arch Intern Med 1984;144:1781-1783.
55. Zuckerman GR, Cornette GL, Clouse RE, et al. Upper gastrointestinal bleeding in patients with chronic renal failure. Ann Intern Med 1978;138:1214-1217.
56. Dorothy CC. Gastrointestinal bleeding in dialysis patients. Nephron 1993;63:132-139.
57. Kumar S, Lesch M. Pericarditis in renal disease. Prog Cardiovasc Dis 1980;22:357-369.
58. Bechar M, Lakke JP, van der Hem GK, et al. Subdural hematoma during long term hemodialysis. Arch Neurol 1972;26:513-516.
59. Galen MA, Steinberg SM, Lowrie FG. Hemorrhagic pleural effusion in patients undergoing chronic dialysis. Ann Intern Med 1975;82:359-361.
60. Milutinovich J, Follette WC, Scribner BH. Spontaneous retroperitoneal bleeding in patients on chronic hemodialysis. Ann Intern Med 1977;86:189-192.
61. Borra S, Kleinfeld M. Subscapular liver hematoma in a patient on chronic hemodialysis. Ann Intern Med 1980;93:574-575.
62. Slusher MM, Hamilton RW. Letter: spontaneous hyphema during hemodialysis. N Engl J Med 1975;293:561.
63. Gordon LA, Somon ER, Rukes JM, et al. Studies in regional hepatization. N Engl J Med 1956;255:1063-1066.
64. Blaufox MD, Hampers CL, Merril JP. Rebound anticoagulation occurring after regional heparinization for hemodialysis. Trans Am Soc Artif Intern Organs 1966;12:207-209.
65. Tolkoff-Rubin NE, Nardini J, Fang LST, et al. Successful hemodialysis of patients at high risk of hemorrhage using the ExVal dialyzer. Dial Transplant 1986;15:125-126.
66. Flanigan MJ, Von Brecht J, Freeman RM, et al. Reducing the hemorrhagic complications of hemodialysis: a controlled comparison of low-dose heparin and citrate anticoagulation. Am J Kidney Dis 1987;9:147-153.
67. Kelleher SP, Schulman G. Severe metabolic alkalosis complicating regional citrate hemodialysis. Am J Kidney Dis 1987;9:235-236.
68. Saltissi D, Morgan C, Westhuyzen J, et al. Comparison of low-molecular-weight heparin (enoxaparin sodium) and standard un-fractionated heparin for haemodialysis anticoagulation. Nephrol Dial Transplant 1999;14:2698-2703.
69. Ivanovich P, Xu CG, Kwaan HC, et al. Studies ofcoagulation and platelet functions in heparin-free hemodialysis. Nephron 1983;33:116-120.
70. Casati S, Moia M, Graziani G, et al. Hemodialysis without anticoagulants: efficiency and hemostatic aspects. Clin Nephrol 1984;21:102-105.
71. Fernandez F, van Ryn J, Ofosu F, et al. The hemorrhagic and antithrombotic effects of dermatan sulphate. Br J Haematol 1986;64:309-317.
72. Boccardo P, Melacini D, Rota S, et al. Individualized anticoagulation with dermatan sulphate for haemodialysis in chronic renal failure. Nephrol Dial Transplant 1997;12:2349-2354.
73. Dawson A, Lawinski C, Weston M, et al. Sulfinpyrazone as a method of keeping dialysis membranes clean. In: Frost TH, ed. Technical aspects of renal disease, Bath, England: Pitman Press, 1978.
74. Zusman RM, Rubin RH, Cato AE, et al. Hemodialysis using prostacyclin instead of heparin as the sole antithrombotic agent. N Engl J Med 1981;304:934-939.
75. Swartz RD, Flamenbaum W, Dubrow A, et al. Epoprostenol (PGI, prostacyclin) during high-risk hemodialysis: preventing further bleeding complications. J Clin Pharmacol 1988;28:818-825.
76. Lin FK, Suggs S, Lin CH. Cloning and expression of the humanery thropoietin gene. Proc Nat Acad Sci U S A 1985;82:7580-7584.
77. Eschbach JW, Egrie JC, Downing MR, et al. Correctionof theanemia and end-stage renal disease with recombinant human erythropoietin: results of a phase I and II clinical trial. N Engl J Med 1987;316:73-78.
78. Van Geet C, Hauglustaine D, Verresen L, et al. Haemostatic effects of recombinant human erythropoietin in chronic haemodialysis patients. Thromb Haemost 1989;61:117-121.
79. NKF-DOQI. Clinical practice guidelines: treatment of anemia of chronic renal failure. Am J Kidney Dis 1997;30:S192-S237.
80. Besarab A, Bolton WK, Browne JK, et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 1998;339:584-590.
81. Janson PA, Jubelirer SJ, Weinstein MJ, et al. Treatment of the bleeding tendency in uremia with cryoprecipitate. N Engl J Med 1980;303:1318-1322.
82. Mannucci PM, Remuzzi G, Pusinieri F, et al. Deamino-8-d-arginine vasopressin shortens the bleeding time in uremia. N Engl J Med 1983;308:8-12.
83. Vigan G, Mannucci PM, Lattuada A, et al. Subcutaneous injection of desmopressin (DDAVP) shortens the bleeding time in uremia. Am J Hematol 1989;31:32-35.
84. Shapiro MD, Kelleher SP. Intranasal deamino-8-d-argine vasopressin shortens the bleeding time in uremia. Am J Nephrol 1984;4:260-261.
85. Canavese C, Salomone M, Pacitti A, et al. Reduced response of uraemic bleeding time to repeated doses of desmopressin. Lancet 1985;1:867-868.
86. Mannucci PM. Desmopressin (DDAVP) in the treatment of the bleeding disorders: the first 20 years. Blood 1997;90:2516-2521.
87. Livio M, Mannucci PM, Vigano GL, et al. Conjugatedestrogensforthe management of bleeding associated with renal failure. N Engl J Med 1986;315:731-735.
88. Liu YK, Kosfeld RE, Marcum SG. Treatment of uraemic bleeding with conjugated oestrogen. Lancet 1984;2:887-890.
89. Vigan G, Gaspari F, Locatelli M, et al. Dose-effect and pharmacokinetics of estrogens given to correct bleeding time in uremia. Kidney Int 1988;34:853-858.
90. Zoja C, Noris M, Corna D, et al. L-Arginine, the precursor of nitric oxide, abolishes the effect ofestrogens on bleeding time in experimental uremia. Lab Invest 1991;65:479-483.
91. Sloand JA, Schiff MJ. Beneficial effect of low-dose transdermal estrogen on bleeding time and clinical bleeding in uremia. Am J Kidney Dis 1995;26:22-26.
92. Sagripanti A, Cupisti A, Baicchi U, et al. Plasma parameters of the prothrombotic state in uremia. Nephron 1993;63:273-278.
93. Sabovic M, Lavre J, Vujkovac B. Tranexamic acid is beneficial as adjunctive therapy in treating major upper gastrointestinal bleeding in dialysis patients. Nephrol Dial Transplant 2003;18:1388-1391.
94. Hedges SJ, Dehoney SB, Hooper JS, et al. Authors response to 'Tranexamic acid and uremic bleeding: evidence-based treatment recommendations'. Nat Clin Pract Nephrol 2007;3:E3.
95. Lazarus JM, Hakim RM. Medical aspects of hemodialysis. In: Brenner BM, et al., ed. The kidney, Philadelphia: WB Saunders, 1991:2223-2298.
96. Mannucci PM, Canciani MT, Forza I, et al. Changes in health and disease of the metalloprotease that cleaves von Willebrand factor. Blood 2001;98.2730-2735.
97. Galbusera M, Noris M, Remuzzi G. Thrombotic thrombocytopenc purpura-then and now. Semin Thromb Haemost 2006;32:81-89.